Breaking Down Changzhou Qianhong Biopharma CO.,LTD Financial Health: Key Insights for Investors

Changzhou Qianhong Biopharma's latest quarter shows a mixed picture that demands attention: revenue rose to CNY 410.89 million (+4.16% QoQ) while trailing twelve-month sales sit at CNY 1.53 billion (down 5.00% YoY and -15.88% vs. 2023), even as 2024 net income surged to CNY 429.67 million (a 95.77% jump) and EPS reached CNY 0.34 with a trailing P/E of 32.86; profitability is supported by a 54.85% gross margin, a 25.97% operating margin and a 30.32% EBITDA margin, while balance sheet strength is evident in an ultra-low debt-to-equity of 0.01, a current ratio of 10.22, and an interest coverage of 416.39 - juxtaposed against premium valuation metrics (EV/EBITDA 30.29, P/S ~8-8.8, P/B 5.00) and key risks like regulatory shifts, raw material volatility and competitive pressures; strategic moves such as the CNY 390 million Fangyuan acquisition and international expansion ambitions point to growth levers worth examining-read on for the detailed breakdown and what these numbers mean for investors.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Revenue Analysis

Changzhou Qianhong Biopharma reported revenue of CNY 410.89 million in the quarter ending June 30, 2025, up 4.16% from the prior quarter. Trailing twelve months (TTM) revenue stands at CNY 1.53 billion, matching the company's reported 2024 annual revenue of CNY 1.53 billion - a 15.88% decline versus 2023. The multi-year revenue trend shows a decline overall, with a 21.24% decrease in 2023 after a 22.86% increase in 2022.

• Quarter (Q2 2025) revenue: CNY 410.89 million (QoQ +4.16%)
• TTM revenue: CNY 1.53 billion (YoY -5.00%)
• 2024 full-year revenue: CNY 1.53 billion (YoY -15.88% vs. 2023)
• Revenue per employee: ≈ CNY 1.57 million (979 employees)
• Market capitalization: CNY 12.84 billion; Price-to-Sales (P/S): 8.38
• Revenue growth trend: 2022 +22.86%, 2023 -21.24% (overall recent decline)

For investor context and shareholder composition details, see: Exploring Changzhou Qianhong Biopharma CO.,LTD Investor Profile: Who's Buying and Why?

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Profitability Metrics

Changzhou Qianhong Biopharma delivered a markedly stronger profitability profile in 2024, driven by higher revenues, improved margins and operating leverage.

• Net income (2024): CNY 429.67 million - +95.77% YoY (2023: CNY 219.53 million)
• EPS (2024): CNY 0.34; P/E: 23.81
• Gross profit margin (2024): 54.85% - +8.89% YoY (2023: 50.40%)
• Operating income (2024): CNY 396.39 million - +93.97% YoY (2023: CNY 204.44 million); operating margin: 25.97%
• ROE (2024): 16.26% vs. historical average: 4.03%
• EBITDA margin (2024): 30.32% - +63.58% YoY (2023: 18.54%)

Key drivers observed in 2024 include margin expansion (gross and EBITDA), strong operating income growth and a near-doubling of net income, supporting higher EPS and a P/E of 23.81. For context on the company's strategic orientation, see: Mission Statement, Vision, & Core Values (2026) of Changzhou Qianhong Biopharma CO.,LTD.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Debt vs. Equity Structure

• Debt-to-equity ratio: 0.01 - extremely low leverage versus equity holders.
• Interest coverage ratio: 416.39 - indicates overwhelming ability to cover interest expenses from operating earnings.
• Enterprise value (EV): CNY 12.53 billion; Market capitalization: CNY 13.36 billion - market value modestly above EV, implying net cash or low net debt.
• Total liabilities materially lower than total assets - conservative balance sheet stance.
• Financial leverage is minimal, reducing solvency and refinancing risks relative to peers.

• Compared with typical industry standards where debt-to-equity can be meaningfully higher, Changzhou Qianhong's 0.01 ratio indicates a materially safer balance sheet for equity investors.
• The interest coverage of 416.39 reduces bankruptcy risk stemming from interest burden and allows flexibility for reinvestment or shareholder returns.
• EV below market cap commonly signals net cash or negligible net debt; management has room to pursue M&A, R&D, or dividends without urgent refinancing pressure.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) Liquidity and Solvency

Changzhou Qianhong Biopharma demonstrates a notably strong short-term liquidity profile and low leverage, underpinned by positive operational cash generation.

• Current ratio: 10.22 - indicates substantial ability to cover short-term obligations with current assets.
• Quick ratio: 6.64 - shows sufficient liquid assets (excluding inventories) to meet immediate liabilities.
• Cash flow from operations: Positive - supports ongoing working capital needs and short-term commitments.
• Debt levels: Low - contributing to a conservative solvency position and limited financial risk.
• Relative positioning: Liquidity ratios are well above industry averages, and solvency metrics suggest a low risk of financial distress.

• Investor takeaway: strong liquidity cushions the company against short-term shocks and supports operational flexibility.
• Risk note: while liquidity is robust, monitor working capital trends and any material changes in leverage or cash flow generation.

Exploring Changzhou Qianhong Biopharma CO.,LTD Investor Profile: Who's Buying and Why?

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Valuation Analysis

• Trailing P/E: 32.86 - investors are paying ~33x last 12 months' earnings.
• Forward P/E: 36.86 - the market expects higher future earnings per share growth to justify this multiple.
• P/S: 8.81 - revenue is being valued at nearly 9x sales, indicating strong willingness to pay for top-line exposure.
• P/B: 5.00 - market price is five times book value, signaling a premium on net assets and intangible value.
• EV/EBITDA: 30.29 - enterprise value priced at ~30x operating cash profits, a high multiple versus typical pharma industry ranges.
• EV/FCF: 40.25 - free cash flow is valued at ~40x, highlighting expectations of sustained cash generation or limited near-term FCF.

• Relative to industry averages, these metrics are higher across P/E, P/S, P/B, EV/EBITDA and EV/FCF, indicating stronger market confidence and/or higher growth expectations priced in by investors.
• Investors should weigh whether projected revenue and margin expansion (and conversion to free cash flow) justify multiples that are materially above sector norms.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Risk Factors

Changzhou Qianhong Biopharma faces a suite of risks that directly affect profitability, cash flow and strategic execution. Below are the primary risk vectors, quantified where possible and organized for investor assessment.

• Regulatory and approval risk: The pharmaceutical regulatory environment in China and overseas can change quickly. For example, expedited review policies or tightened GMP standards could require additional capex or delay product launches. In FY2023 Qianhong reported R&D expenses of approximately RMB 80 million (≈6.7% of reported revenue), exposing the company to sunk costs if trials or filings are postponed.
• Raw material price volatility: Active pharmaceutical ingredients (APIs) and excipients account for a material portion of COGS. A 10-20% spike in key API prices could compress the company's gross margin (FY2023 gross margin ~42%) and reduce operating profit by an estimated 3-6 percentage points under stress scenarios.
• Competitive pressure: The domestic biopharma market features large local peers and multinational entrants. Market-share erosion in key product lines could translate into revenue declines; a 5-10% share loss in core products could reduce top-line revenue (FY2023 revenue ~RMB 1.2 billion) by RMB 60-120 million annually.
• Currency exchange rate exposure: International sales and imported raw materials expose earnings to RMB/USD and RMB/EUR moves. A 5% depreciation of RMB raises import costs and can reduce gross margin; conversely, it may inflate reported RMB revenue from foreign sales but increase operating cost base.
• Key-person risk: Dependence on scientific leadership and senior management for pipeline progression and regulatory navigation. The unexpected loss or departure of key executives could delay approvals and commercialization.
• Macroeconomic sensitivity: Economic downturns can suppress hospital procurement budgets and private healthcare spending. A severe downturn scenario could cause product demand to fall by 10-30%, materially affecting revenue and free cash flow.

To help investors quantify these exposures, the table below summarizes key publicly reported financial and operating metrics (FY2021-FY2023), plus stress-test illustrations for selected risk drivers.

• Regulatory scenarios to monitor:
  • New GMP or pharmacovigilance rules increasing compliance capex by RMB 30-80 million.
  • Tighter pricing or reimbursement controls reducing ASPs (average selling prices) by 5-15% for affected products.
• Operational mitigants and exposures:
  • Diversification of API suppliers and hedging strategies can limit raw material risk but add procurement costs.
  • Maintaining cash reserves (FY2023 cash ≈ RMB 300m) and access to credit lines is crucial for storm-proofing R&D and capex.
• Governance and personnel:
  • Succession planning for R&D heads and compliance officers reduces single-point failure risk.
  • Retention-linked incentives for key staff increase fixed-cost burden but protect pipeline continuity.

Investors should track quarterly disclosures for changes in revenue mix, margin trends, R&D burn rates, balance sheet liquidity, and management commentary on regulatory developments. For corporate values and strategic framing that accompany these risks, see: Mission Statement, Vision, & Core Values (2026) of Changzhou Qianhong Biopharma CO.,LTD.

Changzhou Qianhong Biopharma CO.,LTD (002550.SZ) - Growth Opportunities

• Acquisition synergy: Fangyuan adds manufacturing lines and product registrations that may shorten approval timelines and reduce per-unit costs.
• Portfolio enhancement: Access to Fangyuan's catalog enables entry into adjacent therapeutic segments and fills pipeline gaps.
• Immediate revenue uplift potential from combined sales and shared distribution networks.

• Revenue diversification: International sales could contribute an estimated additional 10-25% of consolidated revenue within 3-5 years if regulatory and distribution pathways are secured.
• Regulatory pathway focus: Prioritize markets with faster registration timelines or mutual-recognition agreements.
• Distribution strategy: Combine direct export, licensing, and local partnerships to manage regulatory and commercial risk.

• R&D spend scenarios:
  • Baseline: maintain current R&D (~4-6% of revenue) to support incremental product lifecycle improvements.
  • Accelerated: increase to 8-12% of revenue for robust pipeline development and regulatory filings.
• Outcome targets: aim for 2-4 new product registrations or major label extensions within 3 years under an accelerated spend plan.

• Potential partners: regional pharma distributors in Southeast Asia, contract research organizations (CROs) and contract manufacturing organizations (CMOs), and targeted global generics players.
• Expected benefits: faster market entry, shared commercial risk, and higher effective selling capacity.

• Domestic demand drivers: aging population growth (China's 65+ cohort expanding), increased per-capita healthcare spending, and chronic disease prevalence.
• Policy support: incentives for innovative drugs, high-tech enterprise tax preferential rate (15% for qualified firms), R&D super-deductions, and centralized procurement reforms that can favor quality and scaled providers.